Tigecycline is a broad-spectrum antibiotic that is mainly effective against a wide range of bacteria, including Gram-positive, Gram-negative, anaerobic, and drug-resistant bacteria [1]. It is a glycylcycline antibiotic, which is a derivative of tetracycline, and it works by inhibiting protein synthesis in bacteria [2].

Tigecycline has been shown to be effective against a variety of bacterial infections, such as complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1]. It is also used as a last-resort treatment for infections caused by multi-drug resistant bacteria [3].

According to DrugPatentWatch.com, tigecycline is currently off-patent, which means that generic versions of the drug are available on the market [4]. This can increase accessibility and affordability of the drug, which is important for treating bacterial infections, especially in low-resource settings.

In summary, tigecycline is a broad-spectrum antibiotic that is mainly effective against a wide range of bacteria, including drug-resistant strains. It is used to treat various bacterial infections and is currently available as a generic drug.

Sources:

1. FDA. (2010). TIGECYCLINE injection, for intravenous use. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s013lbl.pdf>
2. Mayo Clinic. (2021). Tigecycline (Intravenous route). <https://www.mayoclinic.org/drugs-supplements/tigecycline-intravenous-route/description/drg-20063021>
3. WHO. (2019). Antibacterial agents for resistant bacteria. <https://www.who.int/news-room/q-a-detail/antibacterial-agents-for-resistant-bacteria>
4. DrugPatentWatch.com. (2022). Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>